Evidence map›Paper›PMID 38251726›Full record

ArticleBritish journal of haematology2024

New standards of care for treatment of diffuse large B-cell lymphoma.

Chathuri Abeyakoon, Gareth P Gregory

Open access · hybridAbstract readComment
PubMed Publisher
In one paragraph

Article in British journal of haematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Tumor-targeted IL2 promotes specific CD8Journal of experimental & clinical cancer research : CR · 2026
    Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Chathuri AbeyakoonLymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-8848-9423
Gareth P GregoryLymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-4170-0682
Monash Health · AUPrincess Margaret Cancer Centre · CA

Funding

Australian NHMRC EL2 FellowshipVictorian Cancer Agency
6 · The paper itself

Abstract

Treatment of newly diagnosed diffuse large B-cell lymphoma with rituximab and CHOP (R-CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence-based therapeutic strategies informed by positive results of randomised clinical trials. Commentary on: Fox et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 2024; 204:1178-1192.

Indexed as

Lymphoma, Large B-Cell, DiffuseStandard of CareAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansPrednisoneRandomized Controlled Trials as TopicRituximabTreatment OutcomeVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristinechemotherapyDLBCLimmunotherapylymphomas

Identifiers

PMID38251726
OpenAlexW4391104484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.